drugset / Trial / NCT00603980

Staccato Alprazolam Abuse Liability

NCT00603980

Phase 1 Completed 31 enrolled Nova Pneuma Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.

Timeline

Start
2008-01
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule 0.5 mg Inhaled
Subject Alprazolam Small molecule 1 mg Inhaled
Subject Alprazolam Small molecule 2 mg Inhaled
Subject Alprazolam Small molecule 4 mg Inhaled

Indications

No indication recorded.